Design, synthesis and biological evaluation of new benzoxazolone/benzothiazolone derivatives as multi-target agents against Alzheimer's disease

dc.contributor.authorErdogan, Merve
dc.contributor.authorKilic, Burcu
dc.contributor.authorSagkan, Rahsan Ilikci
dc.contributor.authorAksakal, Fatma
dc.contributor.authorErcetin, Tugba
dc.contributor.authorGulcan, Hayrettin O.
dc.contributor.authorDogruer, Deniz S.
dc.date.accessioned2026-02-06T18:37:48Z
dc.date.issued2021
dc.departmentDoğu Akdeniz Üniversitesi
dc.description.abstractIn this study, four series of compounds with benzoxazolone and benzothiazolone cores were designed, synthesized and evaluated as multifunctional agents against Alzheimer's disease (AD). Additionally, in order to shed light on the effect of the carbonyl groups of benzoxazolone/benzothiazolone, benzoxazole/benzothiazole-containing analogues were also synthesized and evaluated. Inhibition potency of all final compounds towards cholinesterase enzymes and their antioxidant activity were tested. Subsequently, the anti-inflammatory activity, cytotoxicity, apoptosis, and A beta aggregation inhibition tests were also performed for selected compounds. The results indicated that compounds 11c, a pentanamide derivative with benzothiazolone core, and 14b, a keton derivative with benzothiazolone core, were considered as promising multi-functional agents for further investigation against AD. The reversibility, kinetic and molecular docking studies were also performed for the compounds with the highest AChE 14b (eeAChE IC50 = 0.34 mu M, huAChE IC50 = 0.46 mu M) and BChE 11c (eqBChE IC50 = 2.98 mu M, huBChE IC50 = 2.56 mu M) inhibitory activities. (C) 2020 Elsevier Masson SAS. All rights reserved.
dc.description.sponsorshipScientific and Technological Research Council of Turkey (TUBITAK) [115S192]
dc.description.sponsorshipThis work was supported by the Scientific and Technological Research Council of Turkey (TUBITAK) [grant number 115S192].
dc.identifier.doi10.1016/j.ejmech.2020.113124
dc.identifier.issn0223-5234
dc.identifier.issn1768-3254
dc.identifier.orcid0000-0002-8221-5579
dc.identifier.orcid0000-0001-8737-829X
dc.identifier.orcid0000-0003-3844-6158
dc.identifier.orcid0000-0002-5221-8402
dc.identifier.pmid33395623
dc.identifier.scopus2-s2.0-85098577778
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1016/j.ejmech.2020.113124
dc.identifier.urihttps://hdl.handle.net/11129/12653
dc.identifier.volume212
dc.identifier.wosWOS:000629622800027
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherElsevier France-Editions Scientifiques Medicales Elsevier
dc.relation.ispartofEuropean Journal of Medicinal Chemistry
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260204
dc.subjectAlzheimer's disease
dc.subjectBenzoxazolone
dc.subjectBenzothiazolone
dc.subjectCholinesterase inhibitory activity
dc.subjectAnti-inflammatory
dc.subjectMolecular docking
dc.titleDesign, synthesis and biological evaluation of new benzoxazolone/benzothiazolone derivatives as multi-target agents against Alzheimer's disease
dc.typeArticle

Files